Compare
Phibro Animal Health Corp vs Alkermes plc. vs Indivior Pharmaceuticals, Inc. vs Prestige Consumer Healthcare Inc.
| Latest fiscal year | Phibro Animal Health Corp PAHC | Alkermes plc. ALKS | Indivior Pharmaceuticals, Inc. INDV | Prestige Consumer Healthcare Inc. PBH |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $1.52B | $1.48B | $1.24B | $1.09B |
| Revenue growth (YoY) | +17.1% | -5.2% | +4.3% | -4.3% |
| Gross margin | 33.8% | 86.7% (computed) | 80.2% | 54.7% |
| Operating margin | 12.8% | 17.2% | 21.1% | 28.4% |
| Net margin | 6.6% | 16.4% | 16.9% | 17.5% |
| Net income | $99.72M | $241.66M | $210.00M | $190.30M |
| EPS (Diluted) | $2.43 | $1.43 | $1.64 | $3.91 |
| Operating cash flow | $68.95M | $520.75M | -$27.00M | $257.63M |
| Free cash flow | $9.87M | $480.33M | -$93.00M | $246.45M |
| Cash & equivalents | $61.42M | $388.57M | $195.00M | $63.87M |
| Total assets | $1.50B | $2.49B | $1.20B | $3.49B |
| Total liabilities | $1.12B | $667.70M | $1.30B | $1.61B |
| Shareholders' equity | $385.48M | $1.82B | -$98.00M | $1.89B |
| Return on year-end equity | 25.9% | 13.3% | n/a | 10.1% |
| Shares outstanding | n/a | 165.61M | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Phibro Animal Health Corp | Alkermes plc. | Indivior Pharmaceuticals, Inc. | Prestige Consumer Healthcare Inc. |
|---|---|---|---|---|
| Latest | $1.52B Ended 2026-06-30 | $1.48B Ended 2025-12-31 | $1.24B Ended 2025-12-31 | $1.09B Ended 2026-03-31 |
| 1 year earlier | $1.30B Ended 2025-06-30 | $1.56B Ended 2024-12-31 | $1.19B Ended 2024-12-31 | $1.14B Ended 2025-03-31 |
| 2 years earlier | $1.02B Ended 2024-06-30 | $1.66B Ended 2023-12-31 | $1.09B Ended 2023-12-31 | $1.13B Ended 2024-03-31 |
| 3 years earlier | $977.89M Ended 2023-06-30 | $1.11B Ended 2022-12-31 | $901.00M Ended 2022-12-31 | $1.13B Ended 2023-03-31 |
| 4 years earlier | $942.26M Ended 2022-06-30 | $1.17B Ended 2021-12-31 | n/a | $1.09B Ended 2022-03-31 |